CA2
ENSG00000104267
Target class
Enzyme
Chromosome
8
Approved drugs
8
Clinical candidates (approved and in development)
10
- Approved drugs
- 8
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- CA2
- Gene name
- Carbonic anhydrase 2
- Gene symbol
- CA2
- Protein name
- Carbonic anhydrase 2 (EC 4.2.1.1) (Carbonate dehydratase II) (Carbonic anhydrase C) (CAC) (Carbonic anhydrase II) (CA-II) (Cyanamide hydratase CA2) (EC 4.2.1.69)
- Car2
- CA-II
- CAII
- Gene biotype
- Protein coding
- Gene family
- Carbonic anhydrases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 52
- Highest tissue expression
- 273.65
- Tissue specificity (Gini)
- 0.645
- Tissue specificity (tau)
- 0.872
- KEGG gene identifiers
- hsa:760
- Protein interaction confidence
- 0.8174
- Protein interaction partners
- 20
- R-HSA-1237044
- R-HSA-1247673
- R-HSA-1475029
- R-HSA-9925563
- End position
- 85481493
- Start position
- 85463968
- Chromosome
- 8
- Strand
- Forward
- Cytoplasm . Cell membrane . Note=Colocalized with SLC26A6 at the surface of the cell membrane in order to form a bicarbonate transport metabolon. Displaced from the cytosolic surface of the cell membrane by PKC in phorbol myristate acetate (PMA)-induced cells. .
Publication evidence
- PubMed 15990874
- Tissue specificity (tau)
- 0.872463
- Expression inequality (Gini)
- 0.645326
Expression in transcripts per million
- Stomach
- 273.65
- Colon - Transverse
- 253.34
- Kidney - Cortex
- 138.41
- Kidney - Medulla
- 134.87
- Brain - Spinal cord (cervical c-1)
- 116.81
Expression in transcripts per million
- Stomach273.65
- Colon - Transverse253.34
- Kidney - Cortex138.41
- Kidney - Medulla134.87
- Brain - Spinal cord (cervical c-1)116.81
- Brain - Putamen (basal ganglia)99.47
- Brain - Caudate (basal ganglia)81.63
- Testis80.85
- Brain - Substantia nigra76.48
- Brain - Hippocampus73.95
- Brain - Amygdala73.08
- Liver64.17
- Minor Salivary Gland56.68
- Skin - Not Sun Exposed (Suprapubic)52.93
- Brain - Nucleus accumbens (basal ganglia)52.49
- Brain - Hypothalamus50.3
- Brain - Frontal Cortex (BA9)47.77
- Brain - Cortex45.57
- Brain - Anterior cingulate cortex (BA24)39.94
- Lung31.64
- Skin - Sun Exposed (Lower leg)27.11
- Muscle - Skeletal26.65
- Esophagus - Mucosa22.79
- Thyroid21.28
- Brain - Cerebellum18.2
And 29 more, listed on the interactive page.
- GO:0038166
- GO:0044070
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0045177
- GO:0070062
- GO:0004064
- GO:0004089
- GO:0005515
- GO:0008270
- GO:0018820
Related records
Trials (539)
- 1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
- 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
- 24-hr Intraocular Pressure Control With SIMBRINZA ®
- 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- A Combined Surgical and Medical Approach in Mild Sleep Apnea
- A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
- A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin
- A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma
- A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment
- A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Preventing Migraine Headaches in Children
- A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
- A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD
- A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)
- A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
- A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
- A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache
- A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately
- A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
Drugs (11)
- Acetazolamide Carbonic anhydrase II inhibitor
- Acetazolamide sodium Carbonic anhydrase II inhibitor
- Brinzolamide Carbonic anhydrase II inhibitor
- Dichlorphenamide Carbonic anhydrase II inhibitor
- Dorzolamide Carbonic anhydrase II inhibitor
- Dorzolamide hydrochloride Carbonic anhydrase II inhibitor
- Ethoxzolamide Carbonic anhydrase inhibitor
- Methazolamide Carbonic anhydrase II inhibitor
- Polmacoxib Carbonic anhydrase II inhibitor
- Sulthiame Carbonic anhydrase inhibitor
- Topiramate Carbonic anhydrase II inhibitor